Recruiting Type 2 Diabetes Studies in Flagstaff
About Type 2 Diabetes Clinical Trials in Flagstaff
Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.
There are currently 1 type 2 diabetes clinical trials recruiting participants in Flagstaff, ARIZONA. These studies are seeking a combined 1,100 participants. Research is being sponsored by Viking Therapeutics, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 2 Diabetes Clinical Trials in Flagstaff — FAQ
Are there type 2 diabetes clinical trials in Flagstaff?
Yes, there are 1 type 2 diabetes clinical trials currently recruiting in Flagstaff, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Flagstaff?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Flagstaff research site will contact you about next steps.
Are clinical trials in Flagstaff free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Flagstaff studies also compensate for your time and travel.
What type 2 diabetes treatments are being tested?
The 1 active trials in Flagstaff are testing new therapies including novel drugs, biologics, and treatment approaches for type 2 diabetes.
Data updated March 2, 2026 from ClinicalTrials.gov